236 related articles for article (PubMed ID: 31662528)
1. Simultaneous Integrated Boost in Once-weekly Hypofractionated Radiotherapy for Breast Cancer in the Elderly: Preliminary Evidence.
Bonzano E; Belgioia L; Polizzi G; Siffredi G; Fregatti P; Friedman D; Garelli S; Gusinu M; Vaccara EML; Guenzi M; Corvò R
In Vivo; 2019; 33(6):1985-1992. PubMed ID: 31662528
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.
Scorsetti M; Alongi F; Fogliata A; Pentimalli S; Navarria P; Lobefalo F; Garcia-Etienne C; Clivio A; Cozzi L; Mancosu P; Nicolini G; Vanetti E; Eboli M; Rossetti C; Rubino A; Sagona A; Arcangeli S; Gatzemeier W; Masci G; Torrisi R; Testori A; Alloisio M; Santoro A; Tinterri C
Radiat Oncol; 2012 Aug; 7():145. PubMed ID: 22929062
[TBL] [Abstract][Full Text] [Related]
3. Weekly concomitant boost in adjuvant radiotherapy for patients with early breast cancer: preliminary results on feasibility.
Corvò R; Giudici S; Maggio F; Bevegni M; Sampietro C; Lucido MR; Orsatti M
Tumori; 2008; 94(5):706-11. PubMed ID: 19112945
[TBL] [Abstract][Full Text] [Related]
4. An accelerated hypofractionated schedule with a daily concomitant boost after breast conservation surgery: the feasibility and toxicity.
Ghannam AA; Khedr RA
J Egypt Natl Canc Inst; 2016 Mar; 28(1):39-44. PubMed ID: 26833225
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis.
Dong J; Yang Y; Han D; Zhao Q; Liu C; Sun H; Wang Z; Lin H; Huang W
Technol Cancer Res Treat; 2021; 20():15330338211064719. PubMed ID: 34898315
[No Abstract] [Full Text] [Related]
6. Analysis of Outcomes Using Hypofractionated Tumor Bed Boost Combined With Hypofractionated Whole Breast Irradiation for Early-stage Breast Cancer.
Yu E; Huang D; Leonard K; Dipetrillo T; Wazer D; Hepel J
Clin Breast Cancer; 2017 Dec; 17(8):638-643. PubMed ID: 28629952
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant breast radiotherapy using a simultaneous integrated boost: clinical and dosimetric perspectives.
Alford SL; Prassas GN; Vogelesang CR; Leggett HJ; Hamilton CS
J Med Imaging Radiat Oncol; 2013 Apr; 57(2):222-9. PubMed ID: 23551785
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated Breast Radiation: Shorter Scheme, Lower Toxicity.
Linares I; Tovar MI; Zurita M; Guerrero R; Expósito M; Del Moral R
Clin Breast Cancer; 2016 Aug; 16(4):262-8. PubMed ID: 26454613
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature.
De Rose F; Fogliata A; Franceschini D; Iftode C; Navarria P; Comito T; Franzese C; Fernandes B; Masci G; Torrisi R; Tinterri C; Testori A; Santoro A; Scorsetti M
Breast; 2018 Dec; 42():31-37. PubMed ID: 30149235
[TBL] [Abstract][Full Text] [Related]
10. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
[TBL] [Abstract][Full Text] [Related]
11. Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors.
Ciammella P; Podgornii A; Galeandro M; Micera R; Ramundo D; Palmieri T; Cagni E; Iotti C
Radiat Oncol; 2014 Apr; 9():97. PubMed ID: 24762173
[TBL] [Abstract][Full Text] [Related]
12. A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects.
Guenzi M; Vagge S; Azinwi NC; D'Alonzo A; Belgioia L; Garelli S; Gusinu M; Corvò R
Radiat Oncol; 2010 Nov; 5():111. PubMed ID: 21092219
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy.
De Santis MC; Bonfantini F; Di Salvo F; Dispinzieri M; Mantero E; Soncini F; Baili P; Sant M; Bianchi G; Maggi C; Di Cosimo S; Agresti R; Pignoli E; Valdagni R; Lozza L
Breast; 2016 Oct; 29():90-5. PubMed ID: 27476083
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated whole breast radiotherapy with or without hypofractionated boost in early stage breast cancer patients: a mono-institutional analysis of skin and subcutaneous toxicity.
Palumbo I; Mariucci C; Falcinelli L; Perrucci E; Lancellotta V; Podlesko AM; Marcantonini M; Saldi S; Bini V; Aristei C
Breast Cancer; 2019 May; 26(3):290-304. PubMed ID: 30341747
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated whole-breast radiotherapy and concomitant boost after breast conservation in elderly patients.
Cante D; Franco P; Sciacero P; Girelli G; Pasquino M; Casanova Borca V; Tofani S; Porta MR; Ricardi U
Tumori; 2016; 102(2):196-202. PubMed ID: 26350199
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity.
Deantonio L; Gambaro G; Beldì D; Masini L; Tunesi S; Magnani C; Krengli M
Radiat Oncol; 2010 Nov; 5():112. PubMed ID: 21092288
[TBL] [Abstract][Full Text] [Related]
17. Acute and intermediate toxicity of 3-week radiotherapy with simultaneous integrated boost using TomoDirect: prospective series of 287 early breast cancer patients.
Dicuonzo S; Leonardi MC; Raimondi S; Corrao G; Bagnardi V; Gerardi MA; Morra A; Zerella MA; Zaffaroni M; Pansini F; Cattani F; Luraschi R; Fodor C; Veronesi P; Orecchia R; Rojas DP; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Jul; 23(7):1415-1428. PubMed ID: 33537865
[TBL] [Abstract][Full Text] [Related]
18. Accelerated hypofractionated radiotherapy as adjuvant regimen after conserving surgery for early breast cancer: interim report of toxicity after a minimum follow up of 3 years.
Pinnarò P; Soriani A; Landoni V; Giordano C; Papale M; Marsella A; Marucci L; Arcangeli G; Strigari L
J Exp Clin Cancer Res; 2010 Jan; 29(1):9. PubMed ID: 20100335
[TBL] [Abstract][Full Text] [Related]
19. Assessment of toxicities and outcomes in patients with breast cancer treated with hypofractionated radiotherapy.
Sindhu M; Malik M; Ahmed SF; Valiyaveettil D
Indian J Cancer; 2020; 57(4):423-427. PubMed ID: 33078749
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials.
Pfaffendorf C; Vonthein R; Krockenberger-Ziegler K; Dellas K; Schreiber A; Uhlemann D; Dinges S; Würschmidt F; Andreas P; Weinstrauch E; Eilf K; Rades D; Höller U; Combs SE; Kazmierczak R; Fehlauer F; Schreck U; Zimmer J; Dunst J; Krug D
Breast; 2022 Aug; 64():136-142. PubMed ID: 35691249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
